Article info

Download PDFPDF
Efficacy and safety of NI-0101, an anti-toll-like receptor 4 monoclonal antibody, in patients with rheumatoid arthritis after inadequate response to methotrexate: a phase II study

Authors

  1. Correspondence to Dr Emmanuel Monnet, Clinical Development, NovImmune SA, Geneva, Plan les Ouates 1228, Switzerland; emonnet{at}novimmune.com
View Full Text

Citation

Monnet E, Choy EH, McInnes I, et al
Efficacy and safety of NI-0101, an anti-toll-like receptor 4 monoclonal antibody, in patients with rheumatoid arthritis after inadequate response to methotrexate: a phase II study

Publication history

  • Received October 16, 2019
  • Revised December 3, 2019
  • Accepted December 13, 2019
  • First published December 31, 2019.
Online issue publication 
February 12, 2020

Article Versions

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.